Alpha Teknova (NASDAQ:TKNO) Posts Earnings Results, Beats Expectations By $0.01 EPS

Key Points

• Alpha Teknova beat expectations: Q1 EPS was ($0.08), beating the consensus by $0.01, and revenue came in at $11.08 million versus estimates of $10.23 million.
• The company remains unprofitable with a negative net margin of 42.59% and negative return on equity (23.32%), though liquidity appears strong (current ratio 4.58, debt-to-equity 0.19).
• Insider purchase and mixed outlook: CEO Stephen Gunstream bought 26,000 shares at $2.15, while analysts hold a consensus "Hold" rating with an $8.00 price target and divergent individual ratings.

Alpha Teknova (NASDAQ:TKNO - Get Free Report) announced its quarterly earnings results on Wednesday. The company reported ($0.08) earnings per share for the quarter, topping analysts' consensus estimates of ($0.09) by $0.01, FiscalAI reports. The business had revenue of $11.08 million for the quarter, compared to analysts' expectations of $10.23 million. Alpha Teknova had a negative return on equity of 23.32% and a negative net margin of 42.59%.

Alpha Teknova Stock Performance

TKNO traded down $0.10 during trading hours on Wednesday, hitting $3.64. The company's stock had a trading volume of 120,338 shares, compared to its average volume of 195,097. Alpha Teknova has a fifty-two week low of $1.91 and a fifty-two week high of $7.48. The company has a current ratio of 4.58, a quick ratio of 3.64 and a debt-to-equity ratio of 0.19. The firm has a market capitalization of $195.14 million, a PE ratio of -11.03 and a beta of 0.47. The company has a 50-day simple moving average of $2.81 and a 200 day simple moving average of $3.60.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a "sell (d-)" rating on shares of Alpha Teknova in a research report on Monday, April 20th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $8.00.

Insider Buying and Selling

In other Alpha Teknova news, CEO Stephen Gunstream bought 26,000 shares of the stock in a transaction that occurred on Friday, March 6th. The shares were purchased at an average cost of $2.15 per share, for a total transaction of $55,900.00. Following the transaction, the chief executive officer directly owned 269,497 shares in the company, valued at $579,418.55. The trade was a 10.68% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 12.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Alpha Teknova

Several large investors have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. increased its position in shares of Alpha Teknova by 68.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 90,595 shares of the company's stock valued at $470,000 after purchasing an additional 36,763 shares during the period. Geode Capital Management LLC increased its position in shares of Alpha Teknova by 64.4% during the 2nd quarter. Geode Capital Management LLC now owns 298,850 shares of the company's stock valued at $1,468,000 after purchasing an additional 117,016 shares during the period. JPMorgan Chase & Co. increased its position in shares of Alpha Teknova by 123.1% during the 2nd quarter. JPMorgan Chase & Co. now owns 8,163 shares of the company's stock valued at $40,000 after purchasing an additional 4,504 shares during the period. New York State Common Retirement Fund acquired a new position in shares of Alpha Teknova during the 2nd quarter valued at $96,000. Finally, Marshall Wace LLP increased its position in shares of Alpha Teknova by 83.0% during the 2nd quarter. Marshall Wace LLP now owns 90,032 shares of the company's stock valued at $442,000 after purchasing an additional 40,825 shares during the period. 13.81% of the stock is currently owned by institutional investors and hedge funds.

Alpha Teknova Company Profile

Alpha Teknova, Inc NASDAQ: TKNO is a life science tools and reagents company that develops, manufactures and distributes proprietary products to support research, drug discovery and biomanufacturing. Its offerings target academic institutions, pharmaceutical and biotechnology firms, and diagnostic developers, with a focus on high-purity reagents and optimized workflows designed to accelerate molecular biology and protein science applications.

The company's portfolio includes molecular biology reagents, cell culture buffers, in vitro translation kits, custom recombinant proteins, high-throughput screening buffers and other specialized formulations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.